Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -54,3 M
Net income 2017 -63,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 12,7 M
EBIT 2018 -60,3 M
Net income 2018 -64,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 2,30x
Capitalization 29,1 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.It... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
10:01p Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
04/27 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Departure of Directors..
04/27 ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submiss..
04/11 ANTHERA PHARMACEUTICALS : Announces Completion of Dosing in the Phase 2 BRIGHT-S..
04/10 ANTHERA PHARMACEUTICALS INC : ANTH The Law Offices of Vincent Wong Reminds Inves..
04/10 Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blis..
04/08 DEADLINE ALERT : Brower Piven Reminds Investors Of The Upcoming Deadline In Clas..
03/31 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
03/31 ANTHERA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
03/30 ANTHERA PHARMACEUTICALS : ANTH) Gains on Positive Test Results
More news
Sector news : Bio Therapeutic Drugs
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 5
Average target price 1,27 $
Spread / Average Target 251%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
Charles V. Olson Chief Technology Officer
William R. Shanahan Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR29
AMGEN, INC.11.29%119 744
CELGENE CORPORATION7.10%96 445
GILEAD SCIENCES, INC.-4.23%89 650
REGENERON PHARMACEUTIC..-0.13%38 968
ACTELION LTD26.44%29 633
More Results